Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR2 | Q9NS75 | 18/20 | 0.71 |
| ▸ | CYSLTR1 | Q9Y271 | 18/20 | 0.71 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.43 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3563160 | 1.00 | CYSLTR2 (0.71) | CYSLTR2CYSLTR1LTB4RLTB4R2PPARA | |
| SCHEMBL13269983 | 0.94 | CYSLTR2 (0.66) | CYSLTR2CYSLTR1LTB4RLTB4R2PPARA | |
| SCHEMBL5270808 | 0.94 | CYSLTR2 (0.69) | CYSLTR2CYSLTR1PPARA | |
| SCHEMBL13269984 | 0.94 | CYSLTR2 (0.66) | CYSLTR2CYSLTR1LTB4RLTB4R2PPARA | |
| SCHEMBL3563235 | 0.92 | CYSLTR2 (0.63) | CYSLTR2CYSLTR1LTB4RLTB4R2 | |
| SCHEMBL3563237 | 0.92 | CYSLTR2 (0.63) | CYSLTR2CYSLTR1LTB4RLTB4R2 | |
| SCHEMBL3563232 | 0.92 | CYSLTR2 (0.63) | CYSLTR2CYSLTR1LTB4RLTB4R2 | |
| SCHEMBL3564225 | 0.91 | CYSLTR2 (0.69) | CYSLTR2CYSLTR1PPARA | |
| SCHEMBL3564226 | 0.91 | CYSLTR2 (0.69) | CYSLTR2CYSLTR1PPARA | |
| SCHEMBL3629319 | 0.91 | CYSLTR2 (0.69) | CYSLTR2CYSLTR1PPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1852420-B1 | Indole compounds for treating respiratory disorders | ONO PHARMACEUTICAL CO (JP) | 2012-10-17 | — | — | EP | disclosed |
| US-7728023-B2 | Indole compound and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-06-01 | — | — | US | disclosed |
| US-20080188532-A1 | Indole Compound and Use Thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-08-07 | — | — | US | disclosed |
| EP-1852420-A1 | INDOLE COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-11-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188532-A1 | Indole Compound and Use Thereof | CYSLTR1, LTC4S, IDO1 | CYSLTR2 4/4885CYSLTR1 1/4885LTB4R 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.